Nanshin Pharmaceutical: Planning to acquire assets of a pharmaceutical technology group.

Nanxin Pharmaceutical announced on July 30th that the closing price of the stock has deviated by 30% for three consecutive trading days, which constitutes abnormal fluctuations in stock trading. After verification, the daily operations are normal, with no significant changes or adjustments in the market environment or industry policies, and the internal production and operation order is normal. The company is currently planning to purchase certain domestic pharmaceutical technology assets, but it is not yet certain whether it constitutes a major asset restructuring. As of now, this matter is still in the planning stage, and the company has not signed a letter of intent or other formal agreement with the related parties, so there is significant uncertainty as to whether it can be successfully implemented.